
|Articles|September 18, 2014
- Melanoma (Issue 3)
- Volume 3
- Issue 1
Inducing an Immune Response With a Patient’s Tumor
Author(s)Lawrence Fong, MD
Lawrence Fong, MD, discusses the systemic antitumor effect and clinical response in a phase II trial of intratumoral electroporation of plasmid interleukin-12 (IL-12) in patients with advanced melanoma.
Lawrence Fong, MD, associate professor, Department of Medicine (Hematology/Oncology), University of California, San Francisco, discusses the systemic antitumor effect and clinical response in a phase II trial of intratumoral electroporation of plasmid interleukin-12 (IL-12) in patients with advanced melanoma.
View more about immunotherapies for melanoma > >
Articles in this issue
about 11 years ago
Partnering T-VEC With a Targeted Agent for the Treatment of Melanomaabout 11 years ago
Immunotherapy Combinations for the Treatment of Melanoma






































